During the past decade, National Heart, Lung and Blood Institute (NHLBI) conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 3 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Heart, Lung and Blood Institute (NHLBI)" #1 sponsor was "National Heart, Lung, and Blood Institute (NHLBI)" with 98 trials, followed by "Alexion" with 2 trials sponsored, "University of Pennsylvania" with 2 trials sponsored, "Johns Hopkins University" with 1 trials sponsored and "LMU Klinikum" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Heart, Lung and Blood Institute (NHLBI)" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Children's Hospital Colorado" with 1 trials as a collaborator and "Children's Hospital Medical Center, Cincinnati" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "National Heart, Lung and Blood Institute (NHLBI)" are "Healthy" (17 trials), "Coronary Disease" (13 trials), "Hypertrophic Cardiomyopathy" (10 trials), "Atherosclerosis" (9 trials) and "Hypertension" (9 trials). Many other conditions were trialed in "National Heart, Lung and Blood Institute (NHLBI)" in a lesser frequency.

Most popular intervention types in "National Heart, Lung and Blood Institute (NHLBI)" are "Drug" (38 trials), "Procedure" (18 trials), "Other" (4 trials), "Device" (3 trials) and "Diagnostic Test" (2 trials). Other intervention types were less common.

The name of intervention was led by "Magnetic resonance imaging" (3 trials), "Angiotensin II type 1 receptor antagonists" (2 trials), "Cyclosporine" (2 trials), "G-CSF" (2 trials) and "Losartan" (2 trials). Other intervention names were less common.

The vast majority of trials in "National Heart, Lung and Blood Institute (NHLBI)" are 103 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "National Heart, Lung and Blood Institute (NHLBI)". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 104 completed trials in National Heart, Lung and Blood Institute (NHLBI), undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in National Heart, Lung and Blood Institute (NHLBI), 15 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".